Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | casein kinase 2, alpha prime polypeptide | No references | |
Homo sapiens | PAS domain containing serine/threonine kinase | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Trypanosoma cruzi | casein kinase II, alpha chain, putative | casein kinase 2, alpha prime polypeptide | 350 aa | 319 aa | 50.2 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | CMGC family protein kinase | 0.0082 | 1 | 0.5 |
Echinococcus granulosus | casein kinase ii subunit alpha | 0.0082 | 1 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0082 | 1 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0082 | 1 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0082 | 1 | 0.5 |
Echinococcus multilocularis | casein kinase ii subunit alpha | 0.0082 | 1 | 0.5 |
Trypanosoma brucei | Casein kinase II | 0.0082 | 1 | 1 |
Trypanosoma cruzi | casein kinase II, putative | 0.0082 | 1 | 0.5 |
Loa Loa (eye worm) | CMGC/CK2 protein kinase | 0.0082 | 1 | 1 |
Toxoplasma gondii | CMGC kinase, CK2 family | 0.0082 | 1 | 0.5 |
Schistosoma mansoni | protein kinase | 0.0082 | 1 | 0.5 |
Plasmodium vivax | casein kinase 2, alpha subunit, putative | 0.0082 | 1 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0082 | 1 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0082 | 1 | 0.5 |
Leishmania major | casein kinase II, putative | 0.0082 | 1 | 0.5 |
Giardia lamblia | Kinase, CMGC CK2 | 0.0082 | 1 | 0.5 |
Plasmodium vivax | unspecified product | 0.0082 | 1 | 0.5 |
Plasmodium falciparum | casein kinase 2, alpha subunit | 0.0082 | 1 | 0.5 |
Entamoeba histolytica | protein kinase domain containing protein | 0.0082 | 1 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0082 | 1 | 0.5 |
Entamoeba histolytica | casein kinase, putative | 0.0082 | 1 | 0.5 |
Onchocerca volvulus | 0.0055 | 0.648 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | <= 10 uM | Inhibition of N-terminal GST-tagged human recombinant PASK kinase domain (879 to 1323 residues) expressed in insect cells using MBP protein substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based radiochemical assay | PATENT. | No reference |
IC50 (binding) | <= 10 uM | Inhibition of human recombinant PASK using Ulight-peptide substrate incubated for 2 hrs by TR-FRET assay | PATENT. | No reference |
IC50 (binding) | <= 10 uM | Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay | PATENT. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.